Burosumab treats x-linked patients with hypophosphatemia (XLH) by antagonizing FGF23, increasing renal tubular phosphate reabsorption and normalizing serum phosphorus concentrations [69]. The gene discussed is FGF23; the disease is hypophosphatemia.